RET and thyroid cancer: Thus, ATM deficient thyroid cancer cells bearing BRAFV600E, KRASG12R or CCDC6-RET displayed higher proliferative ability, lower apoptotic rate and greater aggressiveness than NC-transfected cells in vitro.